Introduction
============

Hepatocellular carcinoma (HCC) remains one of the main malignancies worldwide with a poor 5-year survival rate ([@b1-or-40-01-0226]--[@b4-or-40-01-0226]). Generally, patients are diagnosed with HCC at an advanced stage, and a large number of HCC patients show intrahepatic metastasis and postoperative recurrence ([@b5-or-40-01-0226]). In the Chinese population, the development of HCC has been associated with the hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in most patients ([@b6-or-40-01-0226]). The long-term symptoms of inflammation, chronic hepatitis and cirrhosis contribute to the virus-initiated tumorigenic process ([@b7-or-40-01-0226],[@b8-or-40-01-0226]). For the treatment of HCC, liver transplantation or tumor resection is always the most effective treatment. Furthermore, the high rate of metastasis or postsurgical recurrence remains an obstacle to a better prognosis of HCC patients ([@b9-or-40-01-0226],[@b10-or-40-01-0226]). Thus, it is imperative to explore the mechanism of HCC, which may lead to novel insights for the diagnosis and treatment of HCC patients.

Long non-coding RNAs (lncRNAs) include the recently identified class of non-protein coding RNA transcripts of 200 nucleotides to 100 kb in length ([@b11-or-40-01-0226]--[@b13-or-40-01-0226]). Accumulating evidence has demonstrated that lncRNAs may contribute to various biological processes, including proliferation, apoptosis, invasion and metastasis ([@b14-or-40-01-0226]--[@b16-or-40-01-0226]). However, the particular mechanisms of many lncRNAs remain vague. lncRNA PVT1 is located on chromosomal region 8q24, which is a well-known cancer-related region ([@b17-or-40-01-0226]). Previous studies have confirmed that the overexpression of PVT1 accelerates the development and progression of cancer and reduces the chemosensitivity of cancer patients. Although, compared with normal liver tissues, PVT1 showed a high expression in HCC, improved proliferation and predicted recurrence, the precise functions and mechanism of PVT1 in HCC remain to be elucidated ([@b18-or-40-01-0226]--[@b20-or-40-01-0226]).

miRNAs refer to small non-coding RNAs with nearly 20 nucleotides. Recent studies have confirmed that lncRNAs can affect HCC via combining the expression of miRNAs ([@b21-or-40-01-0226],[@b22-or-40-01-0226]). For example, Liu *et al* ([@b21-or-40-01-0226]) found that lncRNA FTX inhibited the proliferation and metastasis of HCC by binding to miR-374a. Zhu *et al* ([@b22-or-40-01-0226]) revealed that lncRNA LINC00052 inhibited the invasion and migration of HCC by binding to miR-452-5p. Therefore, it is of great significance to further explore the miRNA expression profile associated with lncRNA in HCC in order to identify novel therapeutic strategies.

In the present study, we validated the differential PVT1 expression in normal liver and HCC. Furthermore, we combined the miRNA expression profile after silencing PVT1 expression and miRNA target prediction algorithms to explore the underlying target genes related to PVT1 in HCC. Bioinformatics analysis, involving Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), protein-protein interactions (PPIs) and network analyses, was utilized to explore the underlying functions, pathways and networks of the target genes ([@b23-or-40-01-0226]--[@b26-or-40-01-0226]). Furthermore, the relationship between PVT1 and the clinical parameters in HCC was confirmed based on the original data in the TCGA database. A flow chart of the present study is shown in [Fig. 1](#f1-or-40-01-0226){ref-type="fig"}.

Materials and methods
=====================

### Cell culture and siRNA transfection

Human HCC cells (SMMC-7721) were obtained from the American Type Culture Collection (ATCC), and the SMMC-7721 cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% CO~2~. The Lenti-siRNA vector of PVT1 was produced by GeneChem (Shanghai, China) (sense, 5′-CCCAACAGGAGGACAGCUUTT-3′ and antisense, 5′-AAGCUGUCCUCCUGUUGGGTT-3′). siRNA vectors of PVT1 were transfected into HCC cells according to the manufacturer\'s protocol.

### miRNA microarray analysis

The sample analysis and miRNA microarray hybridization were completed by Kangchen Bio-tech (Shanghai, China). Briefly, miRNA labeling was performed using the miRCURY^™^ Array Power Labeling kit (cat. no. 208032-A; Exiqon, Vedbaek, Denmark). Then, the labeled sample was combined with 2X Hybridization buffer (Phalanx Hyb). Assembly and miRCURY™ Array, was used for miRNA array hybridization. miRNA array scanning and analysis were applied via Axon GenePix 4000B microarray scanner and GenePix pro V6.0 software (Molecular Devices, LLC, Sunnyvale, CA, USA). Differentially expressed miRNAs between PVT1 RNAi and the control groups were identified when fold-change (FC) was ≥2 or ≤0.5, and false discovery rate (FDR) \<1 and P\<0.05.

### Validation of the expression of PVT1 in HCC

The TCGA database (<http://cancergenome.nih.gov/>) is a collection of DNA methylation, RNA-Seq, miRNA-seq, SNP array and exome sequencing ([@b27-or-40-01-0226],[@b28-or-40-01-0226]). TCGA can also be used to further explore the expression of complicated cancer genomics and clinical parameters. In the present study, RNA-Seq data of HCC cases, which were calculated on the IlluminaHiSeq RNA-Seq platform, were obtained from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>), containing 374 HCC cases and 50 adjacent normal liver cases up to July 10, 2017. The original expression data of PVT1 were exhibited as reads per million (RPM) and the expression level of PVT1 was normalized by the Deseq package of R language. Prior to applying further analyses, we log transformed the original expression data for PVT1. The difference expression of PVT1 in various clinicopathological parameters in HCC was acknowledged based on the data from the TCGA database. The diagnostic value of PVT1 was evaluated using the receiver operating characteristic (ROC) curve. Additionally, the genetic alteration of PVT1 in HCC was investigated based on TCGA. Furthermore, Oncomine (<https://www.oncomine.org/>) and GEPIA (<http://gepia.cancer-pku.cn/>) databases were assisted to validate PVT1 expression in HCC ([@b29-or-40-01-0226],[@b30-or-40-01-0226]).

### Target prediction and functional analysis

Twelve target prediction algorithms were used to predict the probable target genes of miRNAs. The 12 corresponding prediction algorithms were miRWalk (<http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/>), miRanda (<http://www.microrna.org>), mirBridge (<http://mirsystem.cgm.ntu.edu.tw/>), DIANA microT v4 (<http://diana.imis.athena-innovation.gr/>), miRMap (<http://mirmap.ezlab.org/>), miRDB (<http://www.mirdb.org/>), miRNAMap (<http://mirnamap.mbc.nctu.edu.tw/>), RNA22 (<https://cm.jefferson.edu/>), Pictar2 (<https://www.mdc-berlin.de/>), RNAhybrid (<https://bibiserv.cebitec.uni-bielefeld.de/>), PITA (<https://genie.weizmann.ac.il/>), and TargetScan (<http://www.targetscan.org/>), and the overlapping target genes were identified via Venn diagrams (<http://bioinformatics.psb.ugent.be/webtools/Venn/>). In addition, the HPA (<http://www.proteinatlas.org>) was used to explore the protein expression of target genes in HCC and normal liver tissues.

To further consider the potential functions, pathways and networks of these target genes, bioinformatics analyses (GO, KEGG and network analyses) were performed ([@b31-or-40-01-0226],[@b32-or-40-01-0226]). In this process, Database for Annotation, Visualization and Integrated Discovery (DAVID: available online: <http://david.abcc.ncifcrf.gov/>) was utilized to perform GO and KEGG analyses, and biological process (BP), cellular component (CC) and molecular function (MF) categories were derived from the GO analysis. Additionally, Cytoscape (version 2.8, <http://cytoscape.org>) was applied to construct the functional network.

### Construction of protein-protein interaction (PPI) network

The interaction pairs of the overlapped target genes were researched by Search Tool for the Retrieval of Interacting Genes (STRING; version 9.0, <http://string-db.org>) ([@b33-or-40-01-0226]). The STRING database provides a worldwide perspective for as many animals and mammals as feasible. The predicted and acknowledged interactions are unified and scored. The interaction pairs in PPI network were selected when the combined score was \>0.4.

### Statistical analysis

SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used for the statistical analysis. Data were expressed as mean ± standard deviation (SD). Differences in the expression of PVT1 in HCC and normal liver and various clinicopathological parameters were estimated by the Student\'s t-test. The comparison between different subgroups was performed by one-way analysis of variance (ANOVA). Kaplan-Meier curves were used to detect the relationship between the PVT1 expression and patient survival in HCC. In addition, the ROC curve was used to predict the clinical diagnostic value of PVT1, which was statistically significant when P\<0.05 (two-sided).

Results
=======

### miRNA profiling associated with lncRNA PVT1

The transfection efficiency was \~90%, and the knockdown efficiency of PVT1 in SMMC-7721 cells was \>75% as detected by RT-qPCR (data not shown). Next, a miRNA microarray assay was applied to detect the differentially expressed miRNAs between PVT1 RNAi and the control groups. We found that 2 miRNAs were upregulated, and 12 miRNAs were downregulated in response to PVT1 knockdown. A summary of the differentially expressed miRNAs is shown in [Fig. 2](#f2-or-40-01-0226){ref-type="fig"} and [Table I](#tI-or-40-01-0226){ref-type="table"}. The top 2 upregulated (miR-302b-5p, miR-5191) and downregulated miRNAs (miR-224-5p, miR-4289) were finally selected as the most significant differentially expressed miRNAs due to the FC, FDR and P-values. Significance was determined via an FC ≥2 or ≤0.5, FDR \<1 and P\<0.05 was applied ([@b34-or-40-01-0226]). We focused on the top two upregulated and downregulated miRNAs to improve the accuracy and stability of the results. The targets of the top dysregulated miRNAs may play key regulation roles in PVT1-related HCC.

### Validation of the expression of PVT1 in HCC

Based on TCGA, 24% cases of PVT1 in HCC were found, which contained amplification, deep deletion and mRNA upregulation ([Fig. 3A](#f3-or-40-01-0226){ref-type="fig"}). To demonstrate the vital role of PVT1 in HCC, a clinical study was performed using the original data in TCGA. The results showed the obvious high expression of PVT1 in HCC compared to that in normal liver tissues (P\<0.001, [Fig. 3B](#f3-or-40-01-0226){ref-type="fig"}). Moreover, a statistically significant higher PVT1 expression was observed in sex (male), ethnicity (Asian) and pathological grade (G3+G4) compared with that in the control groups (P\<0.05; [Fig. 3C-E](#f3-or-40-01-0226){ref-type="fig"} and [Table II](#tII-or-40-01-0226){ref-type="table"}). Moreover, the area under curve (AUC) of PVT1 was 0.822 (95% CI, 0.780--0.863), indicating a moderate diagnostic value of the PVT1 expression in HCC ([Fig. 3F](#f3-or-40-01-0226){ref-type="fig"}). Furthermore, we investigated a different PVT1 expression in other clinical parameters of HCC, but no positive results were found based on the TCGA database. In addition, we investigated the relationship between the PVT1 expression and patient survival. A low PVT1 expression was correlated with improved survival (64.31±5.17 months) compared to the high PVT1 expression group (59.59±4.75 months, P=0.241; [Fig. 3G](#f3-or-40-01-0226){ref-type="fig"}) in HCC.

Moreover, the Oncomine and GEPIA databases confirmed the high expression of PVT1 in HCC ([Fig. 4A-C](#f4-or-40-01-0226){ref-type="fig"}). Furthermore, GEPIA demonstrated that patients with a low PVT1 expression have improved overall and disease-free survival, consistent with the results in TCGA ([Fig. 4D and E](#f4-or-40-01-0226){ref-type="fig"}).

### Target prediction and functional analysis

In the present study, 12 miRNA target prediction algorithms were utilized to predict the potential target genes of the four miRNAs. The genes predicted by \>6 algorithms were selected as the final target genes. Among these target genes, 696 genes were predicted by \>2 miRNAs, and these 696 genes were used for the GO and pathway analyses ([Fig. 5](#f5-or-40-01-0226){ref-type="fig"}). The GO analysis indicated that the target genes were involved in complex cellular pathways, such as macromolecule biosynthetic process, compound metabolic process and transcription ([Fig. 6](#f6-or-40-01-0226){ref-type="fig"} and [Table III](#tIII-or-40-01-0226){ref-type="table"}). The KEGG pathway analysis revealed that the MAPK and Wnt signaling pathways may be associated with regulation of the four candidate miRNAs ([Table IV](#tIV-or-40-01-0226){ref-type="table"}). To better identify the relationships between PVT1, miRNAs and target genes, a network was constructed via Cytoscape, and the genes were easily observed from the network ([Fig. 7](#f7-or-40-01-0226){ref-type="fig"}).

### PPI network analysis

The STRING database was applied to construct the PPI network and 1,420 PPI pairs with a combined score of \<0.4 were selected. PHLPP2 (degree, 42) and MAPK8 (degree, 26) had the highest degree and interactions in the PPI network. Then, a sub-network of 269 PPI pairs with \>20 connectivity degrees was constructed for further analysis ([Fig. 8](#f8-or-40-01-0226){ref-type="fig"}). The number of nodes was 96, accounting for 13.79% of all the target genes. The clustering coefficient of PPI network was 0.634, which indicates that the PPI network had high cluster properties.

In addition, the genes associated with the MAPK and Wnt signaling pathways were selected based on the KEGG pathway analysis. Five genes (*PRKCA, MAPK8, PPP3R2, MAP3K7* and *PRKX*) were overlapped based on the Venn diagrams. According to the degree of hub genes in PPI network, *MAPK8* had a high degree (degree, 26). Next, we investigated the preliminary expression level of the five genes based on TCGA, and the original expression data of *PPP3R2* was censored. Thus, based on TCGA, *MAPK8* and *PRKX* were downregulated, whereas *PRKCA* and *MAP3K7* were upregulated in HCC compared to that in normal liver tissues (both P\<0.05, [Fig. 9A-D](#f9-or-40-01-0226){ref-type="fig"}). Furthermore, negative correlations were found between PVT1 and MAPK8 (r=−0.289, P\<0.001, [Fig. 9E](#f9-or-40-01-0226){ref-type="fig"}), PRKCA (r=−0.140, P=0.007, [Fig. 9F](#f9-or-40-01-0226){ref-type="fig"}) and MAP3K7 (r=−0.084, P=0.106, [Fig. 9G](#f9-or-40-01-0226){ref-type="fig"}), whereas a positive correlation was found between PVT1 and PRKX (r=0.154, P=0.003, [Fig. 9H](#f9-or-40-01-0226){ref-type="fig"}). Moreover, based on HPA, weak staining in HCC was observed for MAPK8, whereas moderate staining was observed for PRKCA and PPP3R2 ([Fig. 10A-F](#f10-or-40-01-0226){ref-type="fig"}). Negative staining in both HCC and normal liver tissues was observed for MAP3K7, in contrast with its upregulated expression in TCGA ([Fig. 10G and H](#f10-or-40-01-0226){ref-type="fig"}), whereas moderate staining for PRKX was observed in HCC, inconsistent with its downregulated expression in TCGA ([Fig. 10I and J](#f10-or-40-01-0226){ref-type="fig"}). Based on these results, PRKCA and MAPK8 were all negatively correlated with PVT1, whereas PRKCA was overexpressed in HCC, in contrast with the correlation of PVT1. Thus, only MAPK8 was selected. We hypothesized that PVT1 may influence MAPK8 expression in the MAPK or Wnt signaling pathways to participate in the different biological processes of HCC. However, the precise molecular mechanism of PVT1 in HCC needs further experimental investigation.

Discussion
==========

Previous studies have demonstrated that lncRNAs participates in different biological processes, such as transcription, chromosome remodeling and post-transcriptional processing ([@b35-or-40-01-0226]--[@b37-or-40-01-0226]). Many studies have verified that lncRNAs are associated with the tumorigenesis and development of various types of cancer through various pathways, including the regulation of cell proliferation, metastasis and invasion ([@b38-or-40-01-0226]--[@b40-or-40-01-0226]). Thus, lncRNAs have opened an avenue of cancer genomics.

To date, several studies have investigated the effect of PVT1 on various cancer types. Xu *et al* ([@b41-or-40-01-0226]) demonstrated that PVT1 overexpression encouraged proliferation and invasion in gastric cancer cells via binding to FOXM1, and a high PVT1 expression was associated with the poor prognosis of gastric cancer patients. Chen *et al* ([@b42-or-40-01-0226]) revealed that the overexpression of PVT1 promoted the invasion of non-small cell lung cancer cells. Additionally, PVT1 functioned as a competitive endogenous RNA to regulate the expression of MMP9 via competitively binding to microRNAs. Liu *et al* ([@b43-or-40-01-0226]) showed that PVT1 was an oncogene in prostate cancer by activating miR-146a methylation to improve tumor growth. Nevertheless, the detailed roles for PVT1 in HCC remain undefinable. In the present study, we combined miRNA microarray analysis and TCGA, as well as Oncomine and GEPIA databases to explore the potential biological functions of PVT1 in HCC. We confirmed that PVT1 was an oncogene and highly expressed in HCC, consistent with Yu *et al* and Ding *et al* ([@b18-or-40-01-0226],[@b19-or-40-01-0226]). Moreover, Yu *et al* ([@b18-or-40-01-0226]) revealed that the combined upregulation of two lncRNAs (PVT1 and uc002 mbe.2) offered a new method for the diagnosis of HCC, and the expression of these two lncRNAs was positively correlated with tumor size and clinical stage in HCC patients. Furthermore, Ding *et al* ([@b19-or-40-01-0226]) revealed that the overexpression of PVT1 was strongly associated with the AFP level and could predict recurrence. By comparison, the present study showed that PVT1 expression was positively correlated with sex, ethnicity and pathological grade. The AUC of PVT1 indicated a moderate diagnostic value of PVT1 expression in HCC. Furthermore, the genetic alterations of PVT1 were observed in HCC based on TCGA, which may be correlated with the pathogenesis of HCC.

To the best of our knowledge, the present study was the first to identify the differentially expressed miRNAs associated with PVT1 based on miRNA microarray analysis, and 12 miRNA target prediction algorithms were used to predict the underlying target genes of the differentially expressed miRNAs. According to GO analysis, the target genes were involved in complex cellular pathways, such as macromolecule biosynthetic process, compound metabolism, and transcription. The KEGG pathway analysis revealed that the MAPK and Wnt signaling pathways are potentially correlated with the regulation of the four candidate miRNAs. As reported, the MAPK and Wnt signaling pathways were all associated with proliferation, migration, invasion and prognosis and HCC ([@b44-or-40-01-0226]--[@b48-or-40-01-0226]). Consequently, we hypothesized that PVT1 plays a vital role in HCC by regulating the expression of the four miRNAs via the MAPK or Wnt signaling pathways, which requires further investigation on the precise molecular mechanism of PVT1 in HCC. We also investigated the genes from the MAPK and Wnt signaling pathways and the hub genes from PPI. We hypothesized that PVT1 may influence MAPK8 expression to contribute to different biological processes of HCC. Various *in vitro* and *in vivo* experiments, including cell proliferation, invasion and metastasis assays, and animal models, are needed to verify this hypothesis. The clinical significance and molecular mechanism of PVT1 in the biological function of HCC are to be further researched at the molecular, cellular, tissue and animal levels. Focusing on the new insight of PVT1 in HCC, the present study aimed to provide a potential biomarker or therapeutic target for HCC.

Not applicable.

Funding
=======

The present study was financially supported through grants from the National Natural Science Foundation of China (no. NSFC81560489), the Natural Science Foundation of Guangxi, China (nos. 2016GXNSFBA380039 and 2017GXNSFAA198017) and the Promoting Project of Basic Capacity for Young and Middle-aged University Teachers in Guangxi (no. KY2016LX031) and Medical Excellence Award funded by the Creative Research Development grant from the First Affiliated Hospital of Guangxi Medical University.

Availability of data and materials
==================================

Data used in this study are available upon request to the corresponding author.

Authors\' contributions
=======================

YZ and WM conceived and designed the study. XW, TZ and YQ performed the experiments. YZ and GC wrote the paper. DW and YD reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
==========================================

All experimental protocols were approved by the First Affiliated Hospital of Guangxi Medical University (Nanning, China).

Consent for publication
=======================

Not applicable.

Competing interests
===================

The authors DEC that they have no competing interests.

HCC

:   hepatocellular carcinoma

lncRNAs

:   long non-coding RNAs

TCGA

:   The Cancer Genome Atlas

MEM

:   Multi Experiment Matrix

GO

:   Gene Ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

PPI

:   protein-protein interactions

ROC

:   receiver operating characteristic

BP

:   biological process

CC

:   cellular component

MF

:   molecular function

FDR

:   false discovery rate

AUC

:   area under curve

HBV

:   hepatitis B virus

HCV

:   hepatitis C virus

DMEM

:   Dulbecco\'s modified Eagle\'s medium

FBS

:   fetal bovine serum

DAVID

:   Database for Annotation, Visualization and Integrated Discovery

STRING

:   Search Tool for the Retrieval of Interacting Genes

ANOVA

:   one-way analysis of variance

mean ± SD

:   mean ± standard deviation

FC

:   fold-change

![A flow chart of the present study.](OR-40-01-0226-g00){#f1-or-40-01-0226}

![miRNA clip after PVT1 knock-down in HCC. (A) Volcano plots of miRNAs. Volcano plots were constructed by fold-change and P-values. The vertical lines correspond to P-values, and the horizontal lines represent log2 (fold-change) upregulation and downregulation. The red points indicate the significantly differentially expressed miRNAs. (B) Scatter plot of miRNAs. Scatter plots were generated to assess variations in miRNA expression. The values corresponding to the x-axes and y-axes are the normalized signal values.](OR-40-01-0226-g01){#f2-or-40-01-0226}

![Clinical significance of lncRNA PVT1 in HCC based on the TCGA database. (A) The genetic alteration of PVT1 in HCC, (B) differential expression of PVT1 between HCC and non-cancerous liver tissue, (C) differential expression of PVT1 in male vs. female, (D) white vs. yellow vs. black, (E) G1, G2 vs. G3, G4, (F) ROC curve of PVT1 in HCC, and (G) Kaplan-Meier curves of PVT1 expression in HCC.](OR-40-01-0226-g02){#f3-or-40-01-0226}

![Validation of PVT1 expression in HCC. (A) Validation of PVT1 expression in the cohort of Chen Liver from Oncomine. Normal liver tissues (n=73) and hepatocellular carcinoma tissues (n=97) were included. (B) Validation of PVT1 expression in the cohort of Wurmbach Liver from Oncomine. Normal liver tissues (n=10) and hepatocellular carcinoma tissues (n=35) were included. (C) Normal liver tissues (n=160) and HCC tissues (n=369) were included based on the GEPIA database. (D) Overall survival of PVT1 expression in HCC based on the GEPIA database. (E) Disease-free survival of PVT1 expression in HCC based on the GEPIA database.](OR-40-01-0226-g03){#f4-or-40-01-0226}

![The procedure to achieve 696 genes. a, miR-302b-5p; b, miR-5191; c, miR-224-5p; and d, miR-4289.](OR-40-01-0226-g04){#f5-or-40-01-0226}

###### 

A functional network of Gene Ontology (GO) terms for the potential PVT1 genes in HCC. To further elucidate the functions of the overlapping genes, a function network was constructed according to Cytoscape.
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![MiRNA-mRNA network constructed by Cytoscape. Four miRNAs were selected to draw the miRNA-mRNA network. Red indicates upregulation and green indicates downregulation.](OR-40-01-0226-g07){#f7-or-40-01-0226}

![The PPI network of the target genes. The PPI network was constructed via STRING online and 269 PPI pairs were selected for further analysis.](OR-40-01-0226-g08){#f8-or-40-01-0226}

![Clinical significance of the hub genes in HCC based on the TCGA database. Differential expression of (A) *MAPK8*, (B) *PRKX*, (C) *PRKCA*, and (D) *MAP3K7* between HCC and non-cancerous liver tissue. (E) Negative correlation between PVT1 and MAPK8, (F) PVT1 and PRKCA, (G) PVT1 and MAP3K7, and (H) PVT1 and PRKX.](OR-40-01-0226-g09){#f9-or-40-01-0226}

![Validation of hub gene expression based on the HPA database. (A) MAPK8 was weakly stained in HCC (magnification, ×100), (B) MAPK8 was moderately stained in normal liver (magnification, ×100), (C) PRKCA was moderately stained in HCC (magnification, ×100), (D) PRKCA was weakly stained in normal liver (magnification, ×100), (E) PPP3R2 was moderately stained in HCC (magnification, ×100), (F) PPP3R2 was negatively stained in normal liver (magnification, ×100), (G) MAP3K7 was negatively stained in HCC (magnification, ×100), (H) MAP3K7 was negatively stained in normal liver (magnification, ×100), (I) PRKX was moderately stained in HCC (magnification, ×100), and (J) PRKX was negatively stained in normal liver (magnification, ×100).](OR-40-01-0226-g10){#f10-or-40-01-0226}

###### 

The top 2 upregulated and top 2 downregulated miRNAs.

  Name                      Fold-change   P-value   FDR
  ------------------------- ------------- --------- -------
  Upregulated miRNAs                                
    miR-302b-5p             2.832         0.020     0.441
    miR-5191                2.477         0.013     0.409
  Downregulated miRNAs                              
    miR-224-5p              0.372         0.009     0.398
    miR-4289                0.453         0.002     0.349
    miR-UL22A-5p            0.040         0.001     0.349
    miR-548aa/miR-548t-3p   0.455         0.003     0.371
    miR-544b                0.076         0.006     0.379
    miR-374c-3p             0.465         0.010     0.398
    miR-5009-5p             0.379         0.012     0.407
    miR-138-1-3p            0.392         0.033     0.441
    miR-154-5p              0.360         0.036     0.441
    miR-5003-5p             0.475         0.038     0.441
    miR-195-5p              0.421         0.043     0.441
    miR-3131                0.354         0.049     0.441

###### 

Differential expression of PVT1 of other clinicopathological parameters in HCC based on TCGA.

                             PVT1 expression             
  -------------------- ----- ----------------- --------- ---------
  Tissues                                                
    Normal liver       50    5.489±0.095       12.43     \<0.001
    HCC                374   7.044±0.082                 
  Age (years)                                            
    \<60               169   7.078±1.493       0.305     0.761
    ≥60                201   7.027±1.651                 
  Sex                                                    
    Male               250   7.206±1.624       2.631     0.009
    Female             121   6.749±1.447                 
  Race                                                   
    White              184   6.811±1.525       F=5.436   0.005
    Black              17    6.642±1.575                 
    Asian              158   7.340±1.604                 
  T (tumor)                                              
    T1+T2              275   7.045±1.516       −0.308    0.758
    T3+T4              93    7.104±1.779                 
  Stage                                                  
    I+II               257   7.083±1.534       0.106     0.916
    III+IV             90    7.062±1.750                 
  Pathological grade                                     
    G1+G2              232   6.874±1.491       −2.970    0.003
    G3+G4              134   7.382±1.708                 

###### 

Top 10 enrichment GO terms (BP, CC and MF) for the target genes of miRNAs.

  GO ID        Term                                                                                           Ontology   Count   Fold enrichment   P-value
  ------------ ---------------------------------------------------------------------------------------------- ---------- ------- ----------------- -------------
  GO:0010557   Positive regulation of macromolecule biosynthetic process                                      BP         53      2.197             1.24121E-07
  GO:0051173   Positive regulation of nitrogen compound metabolic process                                     BP         52      2.189             1.89479E-07
  GO:0045941   Positive regulation of transcription                                                           BP         47      2.259             3.37814E-07
  GO:0009891   Positive regulation of biosynthetic process                                                    BP         54      2.106             3.51213E-07
  GO:0045893   Positive regulation of transcription, DNA-dependent                                            BP         42      2.387             3.84168E-07
  GO:0045935   Positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process   BP         50      2.172             4.265E-07
  GO:0051254   Positive regulation of RNA metabolic process                                                   BP         42      2.367             4.81533E-07
  GO:0031328   Positive regulation of cellular biosynthetic process                                           BP         53      2.098             5.24515E-07
  GO:0010628   Positive regulation of gene expression                                                         BP         47      2.193             7.8235E-07
  GO:0010604   Positive regulation of macromolecule metabolic process                                         BP         60      1.898             2.2026E-06
  GO:0005635   Nuclear envelope                                                                               CC         21      2.976             2.61292E-05
  GO:0030424   Axon                                                                                           CC         18      3.287             3.2788E-05
  GO:0030426   Growth cone                                                                                    CC         10      5.380             8.24587E-05
  GO:0030427   Site of polarized growth                                                                       CC         10      5.282             9.56427E-05
  GO:0045202   Synapse                                                                                        CC         28      2.291             9.57691E-05
  GO:0043005   Neuron projection                                                                              CC         27      2.293             0.0001
  GO:0031965   Nuclear membrane                                                                               CC         11      4.377             0.0002
  GO:0016010   Dystrophin-associated glycoprotein complex                                                     CC         6       10.253            0.0002
  GO:0031252   Cell leading edge                                                                              CC         15      3.158             0.0003
  GO:0044459   Plasma membrane part                                                                           CC         105     1.385             0.0003
  GO:0003700   Transcription factor activity                                                                  MF         71      1.857             4.45E-07
  GO:0030528   Transcription regulator activity                                                               MF         95      1.603             2.72E-06
  GO:0043565   Sequence-specific DNA binding                                                                  MF         45      1.891             5.87E-05
  GO:0008092   Cytoskeletal protein binding                                                                   MF         36      1.822             0.0007
  GO:0016563   Transcription activator activity                                                               MF         31      1.929             0.0007
  GO:0051015   Actin filament binding                                                                         MF         9       4.331             0.0010
  GO:0003779   Actin binding                                                                                  MF         26      2.034             0.0010
  GO:0003702   RNA polymerase II transcription factor activity                                                MF         20      2.091             0.0033
  GO:0005127   Ciliary neurotrophic factor receptor binding                                                   MF         3       25.507            0.0045
  GO:0019899   Enzyme binding                                                                                 MF         34      1.658             0.0047

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

The top 10 KEGG pathways from the enrichment analysis of the target genes of miRNAs.

  KEGG ID    KEGG term                        Count   Fold enrichment   P-value   Gene symbol
  ---------- -------------------------------- ------- ----------------- --------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa04010   MAPK signaling pathway           22      2.253             0.0006    *PRKCA, TAOK1, TGFBR1, PPP3R2, STK4*, PRKX, TGFB2, ATF2, MAP3K7, MAPK1, DUSP4, RPS6KA3, RASGRF2, ELK4, ARRB1, MAP3K2, MAPT, PDGFRA, MAPK8, RAPGEF2, CACNA1B, RASA2
  hsa04310   Wnt signaling pathway            15      2.716             0.0011    *PRKCA, TBL1XR1, VANGL1, SMAD4, PPP3R2, SMAD3, FZD3, DAAM1, FZD5, PRKX, MAP3K7, CCND1, PSEN1, PRICKLE2, MAPK8*
  hsa04360   Axon guidance                    13      2.755             0.0024    *SEMA5A, ABLIM1, MAPK1, SEMA6A, PLXNA2, NTN4, PPP3R2, ROBO2, EFNA5, DPYSL2, SLIT1, SRGAP1, EPHA2*
  hsa05210   Colorectal cancer                10      3.255             0.0032    *MAPK1, CCND1, TGFBR1, PDGFRA, SMAD4, SMAD3, FZD3, MAPK8, FZD5, TGFB2*
  hsa05212   Pancreatic cancer                9       3.417             0.0043    *MAPK1, CCND1, TGFBR1, SMAD4, RALA, SMAD3, CDK6, MAPK8, TGFB2*
  hsa05200   Pathways in cancer               21      1.750             0.01500   *PRKCA, XIAP, TGFBR1, MITF, SMAD4, RUNX1T1, SMAD3, CDK6, EGLN1, FZD3, FZD5, STK4, TPM3, TGFB2, MAPK1, CCND1, HDAC2, CDKN2B, PDGFRA, RALA, MAPK8*
  hsa05220   Chronic myeloid leukemia         8       2.916             0.01856   *MAPK1, CCND1, HDAC2, TGFBR1, SMAD4, SMAD3, CDK6, TGFB2*
  hsa04520   Adherens junction                8       2.840             0.0212    *MAP3K7, MAPK1, TGFBR1, SMAD4, SMAD3, PTPN1, MLLT4, VCL*
  hsa04120   Ubiquitin-mediated proteolysis   11      2.195             0.027     *CUL3, UBE2D3, UBE4A, XIAP, NEDD4, UBE2K, UBE2G1, UBA2, UBE2J1, UBE2W, NEDD4L*
  hsa04144   Endocytosis                      13      1.932             0.0350    *DNM3, RAB31, RAB11FIP2, ERBB4, TFRC, NEDD4, ARRB1, TGFBR1, PSD3, PDGFRA, EEA1, NEDD4L, PIP4K2B*

KEGG, Kyoto Encyclopedia of Genes and Genomes.
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